Seaport Therapeutics (SPTX)
Develops lymphatic-targeted oral prodrugs for neuropsychiatric disorders.
$24.88
At close+1.27 (+5.38%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Cost of revenue | 0 | 0 |
| Gross profit | 0 | 0 |
| 28 | 65 | |
| Research & development | 21 | 25 |
| 6 | 41 | |
| General & administrative | 6 | 0 |
| Operating income | −28 | −66 |
| 3 | 3 | |
| Interest income | 2 | 3 |
| Income before tax | −25 | −63 |
| Income tax expense | 1 | 0 |
| Net income from continuing operations | −25 | −63 |
| Net income | −25 | −63 |
| EPS, basic | −$0.48 | −$1.17 |
| EPS, diluted | −$0.48 | −$1.17 |
| Weighted average shares, basic | 53 | 54 |
| Weighted average shares, diluted | 53 | 54 |
| EBITDA | −27 | −65 |
| Depreciation & amortization | 0 | 0 |
| EBIT | −28 | −66 |